UroGen Pharma (URGN) News Today $14.34 +2.31 (+19.20%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$14.03 -0.31 (-2.19%) As of 06/16/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why is UroGen Pharma Up Today?UroGen Pharma Ltd. (NASDAQ:URGN) shares have moved higher today after bullish analyst actions, although the stock remains clouded by an onslaught of class action suits. Investor attention was drawn by several research upgrades and raised price targets, even as multiple law firms issued reminders of pending securities fraud claims with upcoming filing deadlines. Key developments: HC Wainwright upgraded URGN from “neutral” to “buy” and set a $50.00 price target, implying roughly 248.7% upside from prior levels. Shares saw unusually high trading volume following the HC Wainwright upgrade, signaling heightened investor interest. Analysts cited by American Banking News raised URGN’s price targets to $30.00 and $47.00, reflecting stronger earnings and pipeline expectations. At least seven securities law firms—including BFA Law, Levi & Korsinsky, Pomerantz, Schall Law, Bernstein Liebhard, Bronstein Gewirtz & Grossman and Faruqi & Faruqi—filed or reminded investors of class action lawsuits against UroGen for alleged federal securities law violations, with a lead plaintiff deadline of July 28, 2025. Posted 6h agoAI Generated. May Contain Errors. URGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period UroGen Pharma (NASDAQ:URGN) Sees Strong Trading Volume on Analyst UpgradeJune 17 at 1:08 AM | americanbankingnews.comInvestors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 16 at 1:27 PM | globenewswire.comUroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst UpgradeUroGen Pharma (NASDAQ:URGN) Sees Unusually-High Trading Volume After Analyst UpgradeJune 16 at 10:42 AM | marketbeat.comURGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law FirmJune 16 at 10:38 AM | prnewswire.comUroGen Pharma (NASDAQ:URGN) Stock Rating Upgraded by HC WainwrightHC Wainwright raised UroGen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target for the company in a research note on Monday.June 16 at 8:17 AM | marketbeat.comURGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)June 16 at 8:17 AM | globenewswire.comUROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd.June 16 at 8:15 AM | globenewswire.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. ...June 16 at 6:24 AM | gurufocus.comUroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd.June 16 at 5:45 AM | prnewswire.comSG Americas Securities LLC Buys 142,245 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)SG Americas Securities LLC grew its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 701.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 162,514 shares of the company's stock after acquiring an aJune 16 at 3:48 AM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Price Target Raised to $30.00June 16 at 1:31 AM | americanbankingnews.comUroGen Pharma (NASDAQ:URGN) Price Target Raised to $47.00June 16 at 1:31 AM | americanbankingnews.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGenJune 15 at 10:17 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGNJune 15 at 10:00 AM | globenewswire.comUroGen Pharma (NASDAQ:URGN) Shares Gap Up on Analyst UpgradeJune 15 at 1:43 AM | americanbankingnews.comURGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 28 Deadline (NASDAQ:URGN)June 14 at 7:48 AM | globenewswire.comFDA approves UroGen’s Zusduri for non-muscle invasive bladder cancerJune 13, 2025 | yahoo.comUroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20June 13, 2025 | msn.comScotiabank Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) StockScotiabank boosted their price target on shares of UroGen Pharma from $23.00 to $47.00 and gave the stock a "sector outperform" rating in a research report on Friday.June 13, 2025 | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGNJune 13, 2025 | globenewswire.comUroGen Pharma: Lessons Learned And Future OutlookJune 13, 2025 | seekingalpha.comUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens BermanJune 13, 2025 | globenewswire.comUroGen Pharma (NASDAQ:URGN) Shares Gap Up Following Analyst UpgradeUroGen Pharma (NASDAQ:URGN) Shares Gap Up on Analyst UpgradeJune 13, 2025 | marketbeat.comGuggenheim Forecasts Strong Price Appreciation for UroGen Pharma (NASDAQ:URGN) StockGuggenheim boosted their price objective on UroGen Pharma from $15.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday.June 13, 2025 | marketbeat.comUroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGNJune 13, 2025 | prnewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGenJune 12, 2025 | globenewswire.comURGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 12, 2025 | globenewswire.comUroGen Pharma's (URGN) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Thursday.June 12, 2025 | marketbeat.comU.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)June 12, 2025 | businesswire.comThe Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGNJune 12, 2025 | globenewswire.comUS FDA approves Urogen's bladder cancer drugJune 12, 2025 | reuters.comMark Schoenberg Sells 5,162 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) StockJune 12, 2025 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGNJune 12, 2025 | prnewswire.comURGN CLASS ACTION: Invest in UroGen Pharma Ltd.? Contact BFA Law about the Pending Securities Fraud Class Action to Potentially Recover Losses (NASDAQ:URGN)June 12, 2025 | globenewswire.comShareholders that lost money on UroGen Pharma Ltd.(URGN) should contact The Gross Law Firm about pending Class Action - URGNJune 12, 2025 | prnewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than ...June 12, 2025 | stockhouse.comUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens BermanJune 11, 2025 | globenewswire.comClass Action Lawsuit Filed: UroGen Pharma Ltd. (URGN) - Join by July 28, 2025 - Contact Levi & KorsinskyJune 11, 2025 | markets.businessinsider.comDeadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJune 11, 2025 | globenewswire.comURGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitJune 11, 2025 | prnewswire.comUroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 5,162 SharesUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 5,162 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider now owns 153,378 shares in the company, valued at approximately $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.June 11, 2025 | marketbeat.comUroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer SubpopulationJune 10, 2025 | seekingalpha.comUroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens BermanJune 10, 2025 | investing.comURGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud LawsuitJune 10, 2025 | prnewswire.comLowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 10, 2025 | globenewswire.comLevi & Korsinsky Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 – URGNJune 10, 2025 | globenewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGenJune 10, 2025 | prnewswire.comURGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?June 10, 2025 | globenewswire.comShareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGNJune 10, 2025 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGNJune 9, 2025 | globenewswire.com Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.140.90▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼566▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qilian International Holding Group News Today Amphastar Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Structure Therapeutics News Today Aurinia Pharmaceuticals News Today Wave Life Sciences News Today Niagen Bioscience News Today Mineralys Therapeutics News Today Arcus Biosciences News Today Spyre Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts